# REFERENCES

Asuman B and Mehmet O. S., (2005), Formulation and investigation of 5-FU nanoparticles with fctorial design-based studies, I l Farmaco, 60, 840- 846.

Chaudhary A, Tiwari N, Jain V, Singh R. (2011) Microporous bilayer osmotic tablet for colon-specific delivery. Eur J Pharm Biopharm. 78(1):134-40

Chinam N, Arethi B, Pandit H, Singh S P and Meduri V. (2007) Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride. Acta Pharm. 57, 479–89.

Corti G, Cirri M, Maestrelli F, Mennini N, Mura P, (2008) Sustained-release matrix tablets of metformin hydrochloride in combination with triacetyl-b-cyclodex trin. European Journal of Pharmaceutics and Biopharmaceutics 68, 303–309.

Culy CR, Jarvis B, (2001) Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus, Drugs.;61(11):1625-60.

Gohel MC and Amin AF (1998) Formulation optimization of controlled release diclofenac sodium microspheres using factorial design, J. Control. Release, 51, 115-122.

Harika B. Kumar K P (2012) A review on emerging trends of bi-layered tablets. IJPRBS. 1 (5) 1-20.

Herbert A, Lieberman, Lachmen, (1992) Pharmaceutical dosage form. 2nd Ed Marcel Dekker Inc. New York.

Hermans M, Hooge D, (2009) Switch from metformin monotherapy to bitherpy with metformin and repaglinide to achieve glycated haemoglobin target in type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 3, 224–227.

Hoelscher D, Chu PL, Lyness W (2008) fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects Clin Drug Investig. 28(9):573-82.

Hundal RS, Krssak M, Dufour S (2000) Mechanism by which metformin reduces glucose production in Type 2 diabetes. Diabetes 49(12), 2063–2069.

Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J., (2011) A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes, Curr Med Res Opin. Jun;27(6):1157-68

Jain SK, Agrawal GP, Jain NK. (2007) Porous carrier based floating granular delivery system of repaglinide. Drug Dev Ind Pharm. 2007 Apr; 33(4):381-91.

Jain SK, Awasthi AM, Jain NK, Agrawal GP. (2005) Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. J Control Release. 3;107(2):300-9

Krentz AJ, Bailey CJ. (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus, Diabetes, Drugs. 65(3):385-411.

Li S. Lin S, Daggy B S, Mirchandani H L and Chien, Y W, (2003) Effect of HPMC and Carbopol on the release and floating properties of Gastric Floating Drug Delivery System using factorial design, Int. J. Pharm. 253, 13-22.

Liu L, Xu X. (2008) Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int J Pharm. Mar 20;352(1-2):225-30.

Madan J, Sharma AK, Singh R (2009) Fast Dissolving Tablets of Aloe Vera Gel. Tropical Journal of Pharmaceutical Research. 8 (1): 63-70.

Mandal U, Gowda V, Ghosh A, Selvan S, Solomon S, Pal TK (2007) Formulation and optimization of sustained release matrix tablet of metformin HCl 500 mg using response surface methodology. Yakugaku Zasshi. 127(8):1281-90.

Margret C, Venkateswarlu B.S., JadhavAnup Shankarrao1, Debjit B, Jayakar B., Narayana T.V(2010) formulation and Evaluation of Extended Release Tablets containing Metformin HCl, IJCRGG 2, (2), 1320-1329.

Nevin C, Nurhan E, and Ali T (1996) The preparation and evaluation of salbutamol sulphate containing poly(lactic acid-coglycolic acid) microspheres with factorial design-based studies, Int. J. Pharm.,136: 89-100.

Pattanayak DP and Dinda SC (2011) "Bilayer tablet formulation of metformin hydrochloride and glimepiride: A novel approach to improve therapeutic efficacy", Int. J.disc. herbal res. 1, 1-4.

Pelikánova T (2009), Treatment of diabetes in metabolic syndrome, Vnitr Lek. Jul-Aug; 55(7-8):637-45.

Plosker GL and Figgitt DP (2004) Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus, Pharmacoeconomics. 2004; 22(6):389-411.

Raskin P, Klaff L, McGill J, South SA, Hollander P, Khutoryansky N, Hale P M, (2003) Efficacy and safety of combination therapy: repaglinide plus Metformin versus nateglinide plus metformin. Diabetes Care 26, 2063–2068.

Rehab N S, Emad B B and Raguia A S, (2011) Development and optimization of a multiple-unit controlled release formulation of a freely water soluble drug for once-daily administration, Int. J. Pharm., 405, 102-112.

Sahariar M R (2011) Formulation development of bi-layer acetaminophen tablets for extended drug release. Journal of Chemical & Pharmaceutical Research., 3(6):348-360

Sakane N.(2012) Antidiabetic fixed-dose combination tablet for the management of type 2 diabetes, Nihon Rinsho, Jan;70(1):165-70.

Sathali A H and R. K (2012) Enhancement of solubility of repaglinide by solid dispersion technique, Int. J. Chem. Sci., 10(1), 377-390.

Senthil A, Sri P, Mahmud AB, and Gopal N., (2013) Design and Optimization of Directly Compressible Matrix Tablets Of Recrystallized Metformin HCL Using Full Factorial Design, 3rd ICABPS, January, 19-22: psrcentre.org/images/extraimages/113653.pdf

Shigeto M, Katsura M, Matsuda M, Ohkuma S and Kaku K.( 2007) Nateglinide and Mitiglinide, but Not Sulfonylureas, Induce Insulin Secretion through a Mechanism Mediated by Calcium Release from Endoplasmic Reticulum. J Pharmacol Exp Ther, 322:1–7

Soegondo S, Subekti I, Luthariana L, (2004) The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Medica Indonesiana 36, 142–147.

Stein SA, Lamos EM and Davis SN (2012) A review of the efficacy and safety of oral antidiabetic drugs Expert Opin Drug Saf.: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977601/

Thombre A., Appel L., Chidlaw M., (2004) Osmotic drug delivery using swellable-core technology, J. Control. Release. 94, 75– 89.

Vanderbist francis (2007) Multiple units controlled-release floating dosage forms. (WO 2007/106957 A1)

Veltkamp SA, van D J, Collins C, van B M, Kadokura T, Smulders R A, (2012) Combination treatment with ipragliflozin and metfomin: a randomized, double blind, placebo controlled study in patients with type 2 diabetes mellitus. Clinical Therapeutics 34, 1761–1771.

WHO (2013) WHO Model List of Essential Medicines, 16th edition, World Health Organization, p. 30. Retrieved April 25, 2013.